Molecular Targeted Therapy Market to Surpass $246 Billion by 2034 | Exactitude Consultancy

Molecular Targeted Therapy Market Outlook 2025-2034

Luton, Bedfordshire, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- The Molecular Targeted Therapy Market is experiencing robust growth, with an estimated valuation of $127 billion in 2024, projected to reach approximately $246 billion by 2034. This impressive expansion reflects a Compound Annual Growth Rate (CAGR) of about 7.2% over the forecast period. The market’s growth is fueled primarily by the increasing global burden of cancer, advancements in precision medicine, and the expanding role of targeted therapies across various disease indications, including oncology, autoimmune, and rare diseases.

Get a Sample PDF Brochure: https://exactitudeconsultancy.com/reports/65591/molecular-targeted-therapy-market#request-a-sample

Monoclonal antibodies represent a major product segment, known for their specificity and effectiveness in treating cancers. The introduction of biosimilars has helped reduce treatment costs and improve accessibility. In parallel, small molecule inhibitors have gained prominence for their ability to penetrate cell membranes and disrupt disease pathways, especially in hematologic cancers. Moreover, emerging therapies such as CAR-T cell therapy and oncolytic virus therapies are expected to significantly reshape the therapeutic landscape as regulatory approvals increase.

The cancer segment remains the largest application area, driven by growing cancer incidence rates and intensive R&D efforts in oncology. Autoimmune diseases are also emerging as a promising segment, fueled by rising prevalence and an expanding drug pipeline targeting conditions like rheumatoid arthritis and multiple sclerosis. Therapies for rare diseases are gaining momentum due to favorable regulatory frameworks and the opportunity for premium pricing, which is especially attractive for pharmaceutical companies.

In terms of route of administration, oral therapies are preferred for their convenience and compliance benefits, whereas injectable and intravenous routes continue to be essential for delivering biologics like monoclonal antibodies. Hospitals and cancer treatment centers serve as the primary end-users due to their infrastructure and expertise in administering complex therapies. Research institutions are equally important, contributing to drug development and clinical trials that pave the way for novel therapies.

From a mechanism of action perspective, tyrosine kinase inhibitors and immune checkpoint inhibitors are key growth drivers. Tyrosine kinase inhibitors are widely used in hematologic malignancies, while immune checkpoint inhibitors are revolutionizing cancer treatment by enabling the immune system to target tumors more effectively. Gene therapies are also emerging, offering potential curative treatments for previously untreatable conditions.

The market is segmented based on stage of development, with marketed products generating significant revenue and providing a stable return on investment. Meanwhile, the clinical trials segment continues to expand, reflecting the pipeline’s richness and the industry's push toward innovation in addressing unmet medical needs.

Geographically, North America leads the market, contributing approximately 45% of total revenue, due to strong healthcare infrastructure, high R&D investments, and favorable reimbursement policies. However, the Asia-Pacific region is the fastest-growing, expected to expand at a CAGR of nearly 10%. This growth is attributed to rising healthcare expenditure, increasing cancer prevalence, and better access to advanced therapies in countries like China, India, and Japan.

Market dynamics include a range of growth drivers such as rising cancer incidence, technological progress in precision medicine, and the integration of artificial intelligence (AI) in drug development. Regulatory frameworks are evolving to support faster drug approvals, especially for therapies targeting critical and unmet needs. Moreover, economic factors like higher healthcare spending and broader insurance coverage in developing regions are enabling greater access to targeted treatments.

However, the market is not without challenges. High treatment costs continue to limit accessibility, especially in low- and middle-income countries. Regulatory complexities and the need for extensive clinical trials can delay the entry of new therapies into the market. Furthermore, supply chain disruptions, pricing pressures, and the intense competition among pharmaceutical players present additional hurdles to market stability and profitability.

On the opportunity front, emerging markets represent untapped potential, particularly as healthcare systems in these regions become more robust. Collaborations between large pharmaceutical companies and nimble biotech firms are driving innovation and accelerating the drug development pipeline. The growing demand for personalized treatment options is shifting healthcare paradigms, encouraging broader adoption of molecular targeted therapies.

Key players shaping the competitive landscape include Roche, Novartis, Bristol-Myers Squibb, Merck & Co., AstraZeneca, Johnson & Johnson, Amgen, Gilead Sciences, AbbVie, Pfizer, and several others. These companies are investing heavily in R&D and strategic partnerships to stay ahead in a market defined by rapid innovation and clinical advancement.

Buy Now : https://exactitudeconsultancy.com/purchase/?currency=USD&type=single_user_license&report_id=65591

Market Segmentation
By Product Type

• Monoclonal Antibodies: Largest segment; driven by efficacy and specificity.
• Small Molecule Inhibitors: Crucial for solid tumors and hematologic malignancies.
• Other Targeted Therapies: Includes CAR-T cell and oncolytic virus therapies.

By Application

• Oncology (Dominant Application):
  • Breast, Lung, Colorectal Cancer, Leukemia, etc.
• Autoimmune Diseases
• Neurological Disorders
• Rare and Infectious Diseases

By End User

• Hospitals: Largest consumer segment.
• Oncology Clinics / Cancer Treatment Centers
• Research Institutes
• Homecare Settings

By Technology

• In Vitro
• In Vivo

By Distribution Channel

• Direct Sales
• Distributors
• Online Sales

By Route of Administration

• Oral: Rising due to convenience and compliance.
• Injectable / Intravenous: Dominant for biologics and monoclonal antibodies.

By Mechanism of Action

• Tyrosine Kinase Inhibitors
• Monoclonal Antibodies
• Immune Checkpoint Inhibitors
• Gene Therapy

By Stage of Development

• Preclinical
• Clinical Trials (Phase I–III)
• Marketed Products: Core revenue-generating segment.

Regional Analysis

North America

• Market Share: Approximately 45% in 2024, making it the largest regional market globally.
• Key Drivers:
  • Advanced healthcare infrastructure: Widespread access to cutting-edge medical technologies and specialized cancer treatment centers.
  • Strong R&D investment: High expenditure by pharmaceutical companies and research institutions, particularly in the U.S., for oncology-focused drug development.
  • Regulatory Support: The U.S. FDA’s fast-track designations, priority reviews, and breakthrough therapy designations facilitate quicker market entry for innovative molecular targeted therapies.
  • High prevalence of cancer: Growing incidence of cancer types like breast, lung, and colorectal cancer drives demand for personalized treatment.
• Key Markets: United States and Canada, with the U.S. dominating due to robust commercialization pipelines and strong reimbursement coverage.

Europe

• Market Characteristics:
  • Robust regulatory environment: The European Medicines Agency (EMA) supports expedited drug approvals through PRIME (PRIority MEdicines) and orphan drug designations.
  • Favorable reimbursement policies: Countries like Germany, France, and the UK provide substantial insurance coverage, enhancing patient access to expensive therapies.
  • Academic-Industry Collaboration: Strong collaboration between academic institutions and biotech firms fosters clinical development of targeted agents.
  • Population Health Awareness: High awareness and proactive cancer screening initiatives further boost early diagnosis and treatment uptake.
• Key Markets: Germany, France, United Kingdom, Italy, and Spain.

Asia-Pacific

• Growth Rate: Expected to grow at a CAGR of ~10%, making it the fastest-growing region during the forecast period.
• Growth Factors:
  • Rising healthcare investments: Governments in China, India, Japan, and South Korea are heavily investing in cancer care infrastructure.
  • Expanding middle class and private insurance: Rising affordability and increasing uptake of private health insurance policies.
  • Regulatory evolution: Faster drug approval processes in countries like China (NMPA reforms) are encouraging global pharma companies to launch therapies more rapidly.
  • Growing cancer burden: Increasing incidence of lifestyle-related and genetic cancers, along with growing awareness of advanced treatment options.
• Key Markets: China, Japan, India, South Korea, Australia.

Latin America

• Market Trends:
  • Moderate growth trajectory, driven by the expansion of healthcare infrastructure and improved access to diagnostic facilities.
  • Government-led healthcare reforms: Countries like Brazil and Mexico are gradually increasing public healthcare funding and access to biologics.
  • Challenges: Budget constraints, regulatory delays, and unequal access to novel therapies still hinder broad adoption.
  • Opportunities: Expanding partnerships between international pharmaceutical companies and local distributors to penetrate the market.
• Key Markets: Brazil, Mexico, Argentina, Colombia.

Middle East & Africa

• Market Status:
  • Emerging demand, especially in urban centers with high cancer incidence rates and growing medical tourism (e.g., in UAE and South Africa).
  • Infrastructure gaps: Limited number of specialized oncology centers and trained healthcare professionals in many areas.
  • Government initiatives: Some countries are beginning to prioritize cancer in national healthcare agendas (e.g., Saudi Vision 2030 includes healthcare transformation).
  • Private sector growth: Increasing presence of private hospitals offering targeted therapies to high-income patients.
• Key Markets: UAE, Saudi Arabia, South Africa, Egypt.

Browse full Report - https://exactitudeconsultancy.com/reports/65591/molecular-targeted-therapy-market

Market Dynamics

Growth Drivers

1. Rising Cancer Prevalence
   • The increasing global incidence of various cancers—such as breast, lung, colorectal, and hematological malignancies—is a primary driver.
   • According to WHO estimates, cancer cases are projected to rise by over 50% by 2040, creating sustained demand for precision therapies that offer improved efficacy and fewer side effects.
2. Precision Medicine and Biomarker-Driven Strategies
   • Personalized oncology is gaining momentum, with treatments tailored to a patient’s genetic or molecular tumor profile.
   • Biomarker testing enables better identification of patients likely to respond to specific targeted therapies, improving treatment outcomes and reducing unnecessary interventions.
3. AI and Machine Learning in Drug Discovery
   • AI/ML technologies are revolutionizing drug development by identifying potential drug candidates, predicting drug interactions, and optimizing clinical trial designs.
   • Companies are leveraging these tools to reduce development costs and timelines while improving the success rate of novel therapies.
4. Increased Global Healthcare Spending
   • Governments and private entities worldwide are allocating greater budgets to healthcare infrastructure, oncology research, and treatment access.
   • Emerging economies such as China, India, and Brazil are significantly increasing spending to strengthen cancer care delivery.
5. Regulatory Support for Expedited Approvals
   • Regulatory bodies like the FDA and EMA are providing accelerated approval pathways (e.g., fast track, breakthrough therapy, and orphan drug designations) for innovative molecular therapies.
   • These frameworks reduce market entry time, helping patients access cutting-edge treatments faster.

Challenges

1. High Treatment Costs and Affordability Issues
   • Targeted therapies are often prohibitively expensive, limiting accessibility for patients without comprehensive insurance or government support.
   • Economic disparities exacerbate the affordability gap, especially in low- and middle-income countries.
2. Complex and Varied Regulatory Landscapes
   • The drug approval process differs significantly across regions, making global market entry challenging.
   • Navigating diverse regulatory standards increases administrative burden and compliance costs for pharmaceutical companies.
3. Lengthy and Expensive Clinical Trials
   • Targeted therapies require complex clinical trials involving molecular screening and patient stratification, which are time-consuming and costly.
   • High failure rates in late-stage trials further add to the financial risks for developers.
4. Supply Chain Vulnerabilities
   • Geopolitical tensions (e.g., U.S.–China trade issues, EU–UK post-Brexit logistics) and pandemics can disrupt the supply chain of APIs, biologics, and essential inputs.
   • Cold chain requirements for biologic therapies add logistical challenges in many markets.
5. Pricing Pressures and Reimbursement Barriers
   • Payers and health technology assessment (HTA) bodies are demanding cost-effectiveness data before agreeing to reimburse expensive therapies.
   • Governments are increasingly implementing price caps and reference pricing systems, limiting profit margins for developers.

Opportunities

1. Expansion into Emerging Markets
   • Countries across Asia-Pacific, Latin America, and the Middle East are ramping up cancer care capacity and regulatory modernization.
   • Multinational pharmaceutical firms are entering these markets through local partnerships and value-based pricing strategies.
2. Growth in Biosimilars and Next-Gen Targeted Therapies
   • Patent expirations of major targeted biologics (e.g., trastuzumab) open avenues for biosimilar competition, making treatments more affordable.
   • Development of next-generation therapies, such as bispecific antibodies and antibody-drug conjugates (ADCs), represents the future of precision oncology.
3. Rise in Strategic Collaborations and M&A
   • Pharma–biotech collaborations are accelerating research innovation, particularly in genomics, AI-based discovery, and rare cancer therapies.
   • Mergers and acquisitions provide access to proprietary platforms and diversify oncology pipelines.
4. Digital Therapeutics and Telemedicine Integration
   • Integration of telehealth with oncology care enhances patient monitoring, adherence, and real-time symptom management.
   • Digital health platforms also facilitate data collection for clinical trials and real-world evidence generation.
5. Customization through Genetic Profiling and RWE
   • Advanced genomic profiling enables highly targeted, individualized treatment regimens.
   • Real-world evidence (RWE) from electronic health records and patient registries supports post-market surveillance and value-based care models.

Key Competitors

·  Roche Holding AG

·  Novartis AG

·  Pfizer Inc.

·  Bristol-Myers Squibb Company

·  Merck & Co., Inc.

·  AstraZeneca PLC

·  Johnson & Johnson (Janssen Pharmaceuticals)

·  Amgen Inc.

·  Gilead Sciences, Inc.

·  AbbVie Inc.

·  Eli Lilly and Company

·  Sanofi S.A.

·  GlaxoSmithKline plc (GSK)

·  Takeda Pharmaceutical Company Limited

·  Seagen Inc. (formerly Seattle Genetics)

·  Bayer AG

·  Incyte Corporation

·  Exelixis, Inc.

·  Blueprint Medicines Corporation

·  BeiGene Ltd.

Recent Developments:

1. Roche

In June 2023, Roche received approval from the U.S. Food and Drug Administration (FDA) for Columvi (glofitamab), a bispecific monoclonal antibody designed for the treatment of relapsed or refractory diffuse large B-cell lymphoma. This therapy is notable for its fixed-duration treatment regimen, offering patients a defined course of therapy. Columvi has also secured approvals in Canada and the European Union, marking a significant advancement in Roche's oncology portfolio.

2. Novartis

In May 2024, Novartis announced its acquisition of Mariana Oncology, a U.S.-based biotech firm specializing in radioligand therapies (RLT), for up to $1.75 billion. This strategic move aims to enhance Novartis's capabilities in targeted cancer treatments, particularly for small-cell lung cancer. The acquisition complements Novartis's existing RLT portfolio, which includes approved treatments for prostate cancer and gastroenteropancreatic neuroendocrine tumors.

3. Biocon Biologics

Biocon Biologics, a subsidiary of Biocon Ltd., has made significant strides in expanding its biosimilar portfolio. In February 2024, the company signed a settlement and license agreement with Janssen Biotech Inc. and Johnson & Johnson, allowing Biocon to commercialize Bmab 1200, a proposed biosimilar to Stelara® (ustekinumab), in the United States starting February 2025, pending FDA approval. Additionally, Biocon has secured market entry for Bmab 1200 in Europe, the UK, Canada, and Japan, following similar agreements. These developments underscore Biocon's commitment to providing affordable biologic therapies for autoimmune diseases.

4. Bristol Myers Squibb

Bristol Myers Squibb has achieved multiple regulatory milestones with its CAR T cell therapy, Breyanzi (lisocabtagene maraleucel). In May 2024, the FDA expanded Breyanzi's approval to include treatment for relapsed or refractory follicular lymphoma in adults who have undergone two or more prior lines of systemic therapy. This follows earlier approvals for large B-cell lymphoma and chronic lymphocytic leukemia. The expanded indications highlight Breyanzi's growing role in treating various forms of non-Hodgkin lymphoma.

5. Amgen

Amgen has announced plans to expand its biosimilars portfolio, focusing on molecular targeted therapies for various cancers. This strategic initiative aims to address the increasing demand for cost-effective cancer treatments and to enhance Amgen's competitiveness in the oncology biosimilars market. By investing in the development and commercialization of biosimilars, Amgen seeks to provide more accessible treatment options for patients worldwide.

Key Highlights

• Cancer remains the leading application area, while autoimmune disease therapies are expected to see faster growth.
• Hospital settings dominate end-user segments, but homecare adoption is rising.
• Oral therapies are gaining ground for ease of use and better compliance.
• AI-driven innovation and biotech–pharma partnerships are shaping the future.
• Regulatory flexibility for rare diseases and orphan drugs boosts niche markets.

This report is also available in the following languages : Japanese (分子標的治療市場), Korean (분자 표적 치료 시장), Chinese (分子靶向治疗市场), French (Marché des thérapies moléculaires ciblées), German (Markt für molekulare zielgerichtete Therapien), and Italian (Mercato della terapia molecolare mirata), etc.

Get a Sample PDF Brochure: https://exactitudeconsultancy.com/reports/65591/molecular-targeted-therapy-market#request-a-sample

More Research Finding –

Medical High Energy Ray Therapy Equipment Market
The global market for medical high-energy ray therapy equipment is valued at approximately $4.2 billion in 2024. It is projected to reach around $6.8 billion by 2034, reflecting steady growth driven by advances in cancer treatment technologies and increasing demand for radiotherapy. The Compound Annual Growth Rate (CAGR) during the forecast period from 2025 to 2034 is estimated to be approximately 5.1%.
https://exactitudeconsultancy.com/reports/65779/medical-high-energy-ray-therapy-equipment-market

Collimators for Radioisotope Equipment Market
The global market for collimators used in radioisotope equipment is valued at approximately $350 million. The market is projected to reach around $620 million by 2034, driven by increasing demand for diagnostics and therapeutics in nuclear medicine. This reflects a robust Compound Annual Growth Rate (CAGR) of 6.2% over the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65776/collimators-for-radioisotope-equipment-market

Radionuclide Therapy Equipment Market
The global radionuclide therapy equipment market is valued at approximately $4.3 billion, driven by increasing prevalence of cancer and advancements in targeted therapies. The market is projected to reach around $7.8 billion by 2034, reflecting significant growth opportunities primarily attributed to technological advancements, enhanced diagnostic capabilities, and a rising focus on personalized medicine.
https://exactitudeconsultancy.com/reports/65775/radionuclide-therapy-equipment-market

Medical Gas Making Equipment Market
The global medical gas making equipment market is valued at approximately $1.2 billion, driven by the rising demand for medical gases in hospitals and the growth of home healthcare services. The projected market value is expected to reach around $2.3 billion by 2034, reflecting robust growth opportunities in emerging markets and innovations in technology.
https://exactitudeconsultancy.com/reports/65765/medical-gas-making-equipment-market

Potential Therapy Equipment Market
The global market for potential therapy equipment is valued at approximately $18 billion. The market is poised for significant growth, with projections estimating a market value of around $32 billion by 2034, reflecting a robust compound annual growth rate (CAGR) of approximately 6.0% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65746/potential-therapy-equipment-market

Gynecological RF Therapy Apparatus Market
The gynecological RF therapy apparatus market is expected to reach a valuation of approximately $450 million in 2024, driven by an increasing demand for non-invasive treatments and advancements in technology. The market is projected to experience robust growth through 2034, with an estimated value of around $800 million, reflecting the rising adoption of radiofrequency technology in gynecological applications.
https://exactitudeconsultancy.com/reports/65744/gynecological-rf-therapy-apparatus-market

Carbon Dioxide Laser Therapy Machine Market
The global market for Carbon Dioxide Laser Therapy Machines is valued at approximately $1.2 billion in 2024, with projections indicating it could reach around $2.5 billion by 2034. This growth trajectory represents a Compound Annual Growth Rate (CAGR) of roughly 8.1% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65740/carbon-dioxide-laser-therapy-machine-market

House Dust Mite Allergy Treatment Market
The global market for house dust mite allergy treatment is valued at approximately $2.5 billion in 2024, with projections indicating a robust growth trajectory, potentially reaching around $4.2 billion by 2034. This growth reflects a compound annual growth rate (CAGR) of about 5.5% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65727/house-dust-mite-allergy-treatment-market

Oxiracetam for Injection Market
The oxiracetam injection market is poised for significant growth, with an estimated market value of approximately $120 million in 2024. Projections indicate that this market could reach about $300 million by 2034, driven by increasing applications in cognitive enhancement and neuroprotective treatments. The anticipated Compound Annual Growth Rate (CAGR) for the period from 2025 to 2034 is around 9.3%, reflecting robust demand and expanding research into the compound's efficacy.
https://exactitudeconsultancy.com/reports/65710/oxiracetam-for-injection-market

Estradiol Gel Market
The global estradiol gel market is valued at approximately USD 1.2 billion. Anticipating robust growth, the market is projected to reach around USD 2.5 billion by 2034, driven by increasing awareness regarding menopause management, rising geriatric populations, and growing adoption of hormone replacement therapy. This trajectory indicates a Compound Annual Growth Rate (CAGR) of approximately 7.6% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65697/estradiol-gel-market

Progesterone Supplement Market
The global progesterone supplement market is valued at approximately $1.5 billion, with a projected compound annual growth rate (CAGR) of 8.2% during the forecast period of 2025–2034. By 2034, the market is expected to reach around $3.5 billion, driven by increasing awareness of hormonal health and the expanding applications of progesterone in reproductive health therapies.
https://exactitudeconsultancy.com/reports/65665/progesterone-supplement-market

Estrogen Supplement Market
The global estrogen supplement market is valued at approximately $2.5 billion, reflecting increasing consumer awareness surrounding hormone health and wellness. The market is projected to reach around $4 billion by 2034, driven by a Compound Annual Growth Rate (CAGR) of 5.2% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65661/estrogen-supplement-market

Fluorescence Endoscopy System Market
The global fluorescence endoscopy system market is valued at approximately $1.2 billion in 2024 and is projected to reach $2.5 billion by 2034, reflecting a compound annual growth rate (CAGR) of 7.6% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65632/fluorescence-endoscopy-system-market

Medical Neonatal Phototherapy Device Market
The global market for medical neonatal phototherapy devices is valued at approximately $550 million in 2024. It is projected to reach around $1.1 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of about 7.3% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65629/medical-neonatal-phototherapy-device-market

Far Infrared Therapy Unit Market
The global far infrared therapy unit market is valued at approximately $160 million in 2024, with a robust growth trajectory projected for the upcoming decade. By 2034, the market is expected to reach around $450 million, reflecting the rising acceptance of infrared therapy in pain management and recovery processes. This growth represents a Compound Annual Growth Rate (CAGR) of nearly 11% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65627/far-infrared-therapy-unit-market

Mesotherapy Guns Market
The global mesotherapy guns market is valued at approximately $380 million in 2024, driven by escalating demand for non-invasive aesthetic procedures and enhanced skincare solutions. The market is projected to reach around $750 million by 2034, reflecting significant growth due to increasing consumer awareness and advancements in technology. This results in a Compound Annual Growth Rate (CAGR) of approximately 7.4% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65620/mesotherapy-guns-market

Root Canal Alternatives Market
The market for root canal alternatives is valued at approximately $1.2 billion. The sector is anticipated to grow robustly, with a projected market value reaching around $2.5 billion by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of about 8.1% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65609/root-canal-alternatives-market

Dental Nerve Anesthetic Market
The global dental nerve anesthetic market is valued at approximately $2.1 billion in 2024, with a projected growth to around $3.5 billion by 2034. This reflects a robust compound annual growth rate (CAGR) of approximately 5.4% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/65605/dental-nerve-anesthetic-market

Peritoneal Cancer Treatment Market
The global peritoneal cancer treatment market is valued at approximately $5 billion in 2024 and is projected to expand significantly, anticipating a market value of around $8.5 billion by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of 6.2% during the forecast period from 2025 to 2034, driven by advancements in treatment options and increasing patient awareness.
https://exactitudeconsultancy.com/reports/65592/peritoneal-cancer-treatment-market

Molecular Cancer Therapeutics Market
The global molecular cancer therapeutics market is projected to reach approximately $120 billion in 2024, driven by advancements in personalized medicine and an increasing number of targeted therapies. The market is expected to grow at a robust CAGR of 8.5% from 2025 to 2034, indicating a significant demand for innovative treatments that address specific genetic and molecular profiles of tumors.
https://exactitudeconsultancy.com/reports/65590/molecular-cancer-therapeutics-market

Irfan Tamboli (Head of Sales)
Phone: + 1704 266 3234
Email: sales@exactitudeconsultancy.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.